Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11859
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLim, E Jen
dc.contributor.authorTorresi, Josephen
dc.date.accessioned2015-05-16T01:29:20Z
dc.date.available2015-05-16T01:29:20Z
dc.date.issued2014en
dc.identifier.citationRecent Results in Cancer Research. Fortschritte Der Krebsforschung. Progre`s Dans Les Recherches Sur Le Cancer; 193(): 113-33en
dc.identifier.govdoc24008296en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/11859en
dc.description.abstractHepatocellular carcinoma (HCC) is the fifth most prevalent cancer and the third leading cause of cancer-related death, and its incidence is increasing. The majority of HCC cases are associated with chronic viral hepatitis. With over 170 million individuals chronically infected with hepatitis C virus (HCV) worldwide, HCV is currently a serious global health concern, leading to chronic hepatitis, cirrhosis and HCC, thereby causing significant morbidity and mortality. With the incidence of HCV infection increasing, the problem of HCV-associated HCC is expected to worsen as well, with the majority of HCCs developing in the setting of cirrhosis. Thus, it is imperative to provide antiviral therapy to infected individuals prior to the development of established cirrhosis in order to reduce the risk of subsequent HCC. Indeed, the successful eradication of HCV is associated with clinical and histological improvement as well as a greatly reduced risk of subsequent HCC development. Even after the development of cirrhosis, successful viral clearance is still associated with reduced HCC risk. Current standard of care antiviral treatment consists of pegylated interferon-α and ribavirin, but viral clearance rates are suboptimal with this regimen, especially in difficult to treat cohorts. However, there is a myriad of different classes of HCV-specific direct-acting antiviral agents currently in development, which can be used in combination with one another or with standard of care treatment to improve HCV cure rates. Preventative and therapeutic vaccines against HCV remain an area of ongoing research with good progress towards developing an effective vaccine in the future.en
dc.language.isoenen
dc.subject.otherAnimalsen
dc.subject.otherCarcinoma, Hepatocellular.etiology.prevention & controlen
dc.subject.otherHepacivirus.pathogenicityen
dc.subject.otherHepatitis C.complications.prevention & controlen
dc.subject.otherHumansen
dc.subject.otherLiver Neoplasms.etiology.prevention & controlen
dc.titlePrevention of hepatitis C virus infection and liver cancer.en
dc.typeJournal Articleen
dc.identifier.journaltitleRecent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le canceren
dc.identifier.affiliationDepartment of Gastroenterology, Austin Hospital, Heidelberg, Victoria, 3084, Australia,en
dc.identifier.doi10.1007/978-3-642-38965-8_7en
dc.description.pages113-33en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/24008296en
dc.type.austinJournal Articleen
Appears in Collections:Journal articles
Show simple item record

Page view(s)

14
checked on Jun 12, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.